Westlake Village-based MannKind shares soared more than 16 percent Oct. 16 with the announcement that it had closed its $105 million deal with Maryland-based United Therapeutics. The licensing deal provides $45 million in upfront capital to MannKind for the development and commercialization of an inhalable dry powder version of United’s pulmonary arterial hypertension drug treprostinil.…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
